356 related articles for article (PubMed ID: 24408894)
1. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
Terry SY; Abiraj K; Frielink C; van Dijk LK; Bussink J; Oyen WJ; Boerman OC
J Nucl Med; 2014 Feb; 55(2):281-6. PubMed ID: 24408894
[TBL] [Abstract][Full Text] [Related]
2. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Terry SY; Abiraj K; Lok J; Gerrits D; Franssen GM; Oyen WJ; Boerman OC
J Nucl Med; 2014 Nov; 55(11):1849-55. PubMed ID: 25349221
[TBL] [Abstract][Full Text] [Related]
3. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.
Liu Z; Jia B; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Bioconjug Chem; 2010 Mar; 21(3):548-55. PubMed ID: 20184307
[TBL] [Abstract][Full Text] [Related]
4. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Characterization of 4
Lobeek D; Franssen GM; Ma MT; Wester HJ; Decristoforo C; Oyen WJG; Boerman OC; Terry SYA; Rijpkema M
J Nucl Med; 2018 Aug; 59(8):1296-1301. PubMed ID: 29626124
[TBL] [Abstract][Full Text] [Related]
6. Comparison of biological properties of (111)In-labeled dimeric cyclic RGD peptides.
Zheng Y; Ji S; Tomaselli E; Yang Y; Liu S
Nucl Med Biol; 2015 Feb; 42(2):137-45. PubMed ID: 25459111
[TBL] [Abstract][Full Text] [Related]
7. (99m)Tc-3P-RGD2 micro-single-photon emission computed tomography/computed tomography provides a rational basis for integrin αvβ3-targeted therapy.
Fu T; Qu W; Qiu F; Li Y; Shao G; Tian W; Hua Z; Zhang Y; Wang F
Cancer Biother Radiopharm; 2014 Nov; 29(9):351-8. PubMed ID: 25286251
[TBL] [Abstract][Full Text] [Related]
8. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
9. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
10. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the RGD Motif-Containing α
Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
[TBL] [Abstract][Full Text] [Related]
12. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
13. 18F-FP-PEG2-β-Glu-RGD2: A Symmetric Integrin αvβ3-Targeting Radiotracer for Tumor PET Imaging.
Hu K; Tang X; Tang G; Yao S; Yao B; Wang H; Nie D; Liang X; Tang C; He S
PLoS One; 2015; 10(9):e0138675. PubMed ID: 26397833
[TBL] [Abstract][Full Text] [Related]
14. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck.
Beer AJ; Grosu AL; Carlsen J; Kolk A; Sarbia M; Stangier I; Watzlowik P; Wester HJ; Haubner R; Schwaiger M
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6610-6. PubMed ID: 18006761
[TBL] [Abstract][Full Text] [Related]
15. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
16. Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides.
Yang Y; Ji S; Liu S
Bioconjug Chem; 2014 Sep; 25(9):1720-9. PubMed ID: 25144854
[TBL] [Abstract][Full Text] [Related]
17. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an Integrin α
Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
20. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]